Literature DB >> 17620279

The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database.

Brian E Lally1, Frank C Detterbeck, Ann M Geiger, Charles R Thomas, Mitchell Machtay, Antonius A Miller, Lynn D Wilson, Timothy E Oaks, W Jeffrey Petty, Mike E Robbins, A William Blackstock.   

Abstract

BACKGROUND: This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC).
METHODS: The 17-registry 1973 to 2003 dataset from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program was used to create a cohort of patients with NSCLC who had evidence of ipsilateral lymph node involvement diagnosed from 1983 to 1993 and who underwent pnuemonectomy/lobectomy (n = 6148 patients). Heart disease mortality was the primary endpoint: Deaths from other causes were censored, and surviving patients were censored at 10 years. The independent variable was PORT use, and adjustment variables included age at diagnosis, sex, race, year of diagnosis, laterality, location, histology, and the operation performed.
RESULTS: Multivariate analysis revealed that PORT use was associated with an increase in heart disease mortality (hazards ratio [HR], 1.30; 95% confidence interval [95% CI], 1.04-1.61; P = .0193) along with older age, male sex, African-American race, and earlier year of diagnosis. The association was confirmed in the cohort that was diagnosed from 1983 to 1988 (HR, 1.49; 95% CI, 1.11-2.01 [P = .0090]) but not for the cohort that was diagnosed from 1989 to 1993 (HR, 1.08; 95% CI, 0.79-1.48 [P = .6394]).
CONCLUSIONS: The results from this study demonstrated that the risk of heart disease mortality associated with PORT has declined in more recent years. This may be secondary to improvements in the treatment planning and delivery of thoracic radiotherapy. Properly designed, prospective, adjuvant trials will be needed to verify these findings.

Entities:  

Mesh:

Year:  2007        PMID: 17620279     DOI: 10.1002/cncr.22845

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

Review 1.  Cardiac toxicity of lung cancer radiotherapy.

Authors:  Radovan Vojtíšek
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-14

2.  Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Authors:  Cliff G Robinson; Aalok P Patel; Jeffrey D Bradley; Todd DeWees; Saiama N Waqar; Daniel Morgensztern; Maria Q Baggstrom; Ramaswamy Govindan; Jennifer M Bell; Tracey J Guthrie; Graham A Colditz; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Optimized cardiac functional MRI of small-animal models of cancer radiation therapy.

Authors:  El-Sayed H Ibrahim; Dhiraj Baruah; Matthew Budde; Jason Rubenstein; Anne Frei; Rachel Schlaak; Elizabeth Gore; Carmen Bergom
Journal:  Magn Reson Imaging       Date:  2020-08-28       Impact factor: 2.546

4.  Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.

Authors:  D Hardy; C-C Liu; J N Cormier; R Xia; X L Du
Journal:  Ann Oncol       Date:  2010-03-08       Impact factor: 32.976

5.  Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States.

Authors:  Matthew P Smeltzer; Chun Chieh Lin; Feng-Ming Spring Kong; Ahmedin Jemal; Raymond U Osarogiagbon
Journal:  J Thorac Cardiovasc Surg       Date:  2017-04-04       Impact factor: 5.209

Review 6.  Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data.

Authors:  Cécile Le Péchoux
Journal:  Oncologist       Date:  2011-03-04

Review 7.  Proton therapy for post-operative radiation therapy of non-small cell lung cancer.

Authors:  Annemarie Fernandes Shepherd
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 8.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

Review 9.  Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.

Authors:  Josephine Feliciano; Steven Feigenberg; Minesh Mehta
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

10.  Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.

Authors:  Kyle Wang; Kevin A Pearlstein; Nicholas D Patchett; Allison M Deal; Panayiotis Mavroidis; Brian C Jensen; Matthew B Lipner; Timothy M Zagar; Yue Wang; Carrie B Lee; Michael J Eblan; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks
Journal:  Radiother Oncol       Date:  2017-10-16       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.